Figure 4 from Proteomic Profiling of Extracellular Matrix Components from Patient Metastases Identifies Consistently Elevated Proteins for Developing Nanobodies That Target Primary Tumors and Metastases
Year: 2023
Type: other
Abstract: TNC-specific nanobodies recognize human TNC with subnanomolar affinity. A, Clustal W–based sequence alignment of anti-human TNC nanobodies NJT3, NJT4, and NJT6. CDR, complementarity-determining region. B, Immunoblot showing specificity of TNC-specific nanobodies to human TNC protein. The nanobodies do not recognize mouse TNC in supernatants from TNC-overexpressing (OE) cell lines, supernatant from control cells (control sup), or human TNW. C, Anti-TNC nanobodies recognize human TNC in IHC on tissue sections of lung metastases derived from human TNBC cell line LM2. They did not recognize mouse TNC on tissue sections of lung metastases derived from murine TNBC cell line 4T1. The control rabbit monoclonal α-TNC antibody recognizes both human and mouse TNC. D, Dissociation constants (KD) of α -TNC nanobodies to immobilized human TNC protein measured using BLI. KD, ka, and kd values are listed. Black curves, original data; red curves, curve fitting. H&E, hematoxylin and eosin.
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4380790204